Clinical Trials Browser

Active not recruiting × Has results × Rectal Neoplasms × Clear all

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms

NCT03516942 2026-03-13

Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

Active not recruiting

565 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT02293954 2025-11-14

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

Phase NA Active not recruiting

20 enrolled 8 charts

BreastGastrointestinalThoracic

Bile Duct Neoplasms, Breast Neoplasms, Colonic Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Rectal Neoplasms, Carcinoma, Medullary

NCT03975491 2025-09-22

EXACT

Phase NA Active not recruiting

60 enrolled 13 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01696981 2025-07-23

Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)

Phase NA Active not recruiting

154,900 enrolled 15 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT03992456 2024-05-21

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Phase 2 Active not recruiting

12 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Clinical Trials

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

EXACT

Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer